Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [13]
- Comments [0]
- Validations
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA002110 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA002110, RRID:AB_1855512
- Product name
- Anti-PODXL
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human PODXL, Gene description: podocalyxin-like, Alternative Gene Names: Gp200, PC, PCLP, Validated applications: ICC, IHC, WB, Uniprot ID: O00592, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Mesenchymal-endothelial nexus in breast cancer spheroids induces vasculogenesis and local invasion in a CAM model
Atypical focal segmental glomerulosclerosis associated with a new PODXL nonsense variant
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
Podocalyxin influences malignant potential by controlling epithelial–mesenchymal transition in lung adenocarcinoma
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma.
Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer.
Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.
Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
Proteome-wide Epitope Mapping of Antibodies Using Ultra-dense Peptide Arrays
Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.
Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells
Methylation of an intronic region regulates miR-199a in testicular tumor malignancy
Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer
Li A, Muenst S, Hoffman J, Starck L, Sarem M, Fischer A, Hutter G, Shastri V
Communications Biology 2022;5(1)
Communications Biology 2022;5(1)
Atypical focal segmental glomerulosclerosis associated with a new PODXL nonsense variant
Marx D, Caillard S, Olagne J, Moulin B, Hannedouche T, Touchard G, Dupuis A, Gachet C, Molitor A, Bahram S, Carapito R
Molecular Genetics & Genomic Medicine 2021;9(5)
Molecular Genetics & Genomic Medicine 2021;9(5)
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
Borg D, Larsson AH, Hedner C, Nodin B, Johnsson A, Jirström K
Journal of translational medicine 2018 Oct 24;16(1):290
Journal of translational medicine 2018 Oct 24;16(1):290
Podocalyxin influences malignant potential by controlling epithelial–mesenchymal transition in lung adenocarcinoma
Kusumoto H, Shintani Y, Kanzaki R, Kawamura T, Funaki S, Minami M, Nagatomo I, Morii E, Okumura M
Cancer Science 2017;108(3):528-535
Cancer Science 2017;108(3):528-535
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma.
Borg D, Hedner C, Nodin B, Larsson A, Johnsson A, Eberhard J, Jirström K
BMC clinical pathology 2016;16:13
BMC clinical pathology 2016;16:13
Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer.
Larsson AH, Lehn S, Wangefjord S, Karnevi E, Kuteeva E, Sundström M, Nodin B, Uhlén M, Eberhard J, Birgisson H, Jirström K
Journal of translational medicine 2016 May 10;14(1):128
Journal of translational medicine 2016 May 10;14(1):128
Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma.
Heby M, Elebro J, Nodin B, Jirström K, Eberhard J
BMC clinical pathology 2015;15:10
BMC clinical pathology 2015;15:10
Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma
Real F, Saukkonen K, Hagström J, Mustonen H, Juuti A, Nordling S, Fermér C, Nilsson O, Seppänen H, Haglund C
PLOS ONE 2015;10(6):e0129012
PLOS ONE 2015;10(6):e0129012
Proteome-wide Epitope Mapping of Antibodies Using Ultra-dense Peptide Arrays
Forsström B, Axnäs B, Stengele K, Bühler J, Albert T, Richmond T, Hu F, Nilsson P, Hudson E, Rockberg J, Uhlen M
Molecular & Cellular Proteomics 2014;13(6):1585-1597
Molecular & Cellular Proteomics 2014;13(6):1585-1597
Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.
Boman K, Larsson AH, Segersten U, Kuteeva E, Johannesson H, Nodin B, Eberhard J, Uhlén M, Malmström PU, Jirström K
British journal of cancer 2013 Jun 11;108(11):2321-8
British journal of cancer 2013 Jun 11;108(11):2321-8
Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells
Dallas M, Chen S, Streppel M, Sharma S, Maitra A, Konstantopoulos K
American Journal of Physiology-Cell Physiology 2012;303(6):C616-C624
American Journal of Physiology-Cell Physiology 2012;303(6):C616-C624
Methylation of an intronic region regulates miR-199a in testicular tumor malignancy
Cheung H, Davis A, Lee T, Pang A, Nagrani S, Rennert O, Chan W
Oncogene 2011;30(31):3404-3415
Oncogene 2011;30(31):3404-3415
Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer
Larsson A, Johansson M, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, Uhlén M, Jirström K
British Journal of Cancer 2011;105(5):666-672
British Journal of Cancer 2011;105(5):666-672
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human kidney and liver tissues using HPA002110 antibody. Corresponding PODXL RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
